International Clinical Trial: Phase II study of anlotinib combined with sintilimab as first-line treatment for advanced non-liver metastatic colorectal cancer

Geneva, March 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119128) titled 'Phase II study of anlotinib combined with sintilimab as first-line treatment for advanced non-liver metastatic colorectal cancer' on Feb. 24.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: The Second Affiliated Hospital of Naval Medical University

Condition: Advanced colorectal cancer

Recruitment Status: Not Recruiting

Phase: 2

Date of First Enrollment: 2026-02-24

Target Sample Size: Experimental Group (Anlotinib plus Sintilimab):37;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=310661

Published by HT Digital Content S...